President Joe Biden hit the ground running, signing 30 executive orders on healthcare. We can expect the focus on healthcare to continue, including speeding up vaccinations across the country and passing a new stimulus package as the first order of legislative business. Lowering drug prices will also remain a hot topic.
However, the more ambitious policies touted during the campaign, such as allowing Medicare to negotiate directly with pharmaceutical manufacturers, will likely be put on ice given the extremely narrow majorities held by the Democratic party in both chambers of
Congress. A few legislative and regulatory proposals will remain a risk for the pharmaceutical industry. Download the article below to learn what to watch for.